<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carboprost tromethamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carboprost tromethamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carboprost tromethamine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11310" href="/d/html/11310.html" rel="external">see "Carboprost tromethamine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708653"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carboprost should be used only with strict adherence to recommended dosages. </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Experienced physician: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carboprost should be used by medically trained personnel in a hospital that can provide immediate intensive care and acute surgical facilities.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F146277"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Hemabate</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866202"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Hemabate</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F146296"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Abortifacient;</li>
<li>
                        Prostaglandin</li></ul></div>
<div class="block doa drugH1Div" id="F146280"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98ec63b8-c935-4b1d-9462-34e1e5114a6b">Refractory postpartum uterine bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Refractory postpartum uterine bleeding:</b> IM: Initial: 250 mcg; if needed, may repeat at 15- to 90-minute intervals; maximum total dose: 2 mg (8 doses)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88f830ef-188f-447e-9e24-d67f301f404c">Termination of pregnancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Termination of pregnancy:</b> IM: 250 mcg, then 250 mcg at 1.5- to 3.5-hour intervals, depending on uterine response; a 500 mcg dose may be given if uterine response is not adequate after several 250 mcg doses; do not exceed 12 mg total dose or continuous administration for &gt;2 days. <b>Note:</b> A 100 mcg test dose may be considered.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991964"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use with caution in patients with a history of renal disease; use is contraindicated in patients with active renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50989301"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use with caution in patients with a history of hepatic disease; use is contraindicated in patients with active hepatic impairment.</p></div>
<div class="block doe drugH1Div" id="F146281"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F146260"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not always defined. Effects due to increased smooth muscle contractility are most common and are generally transient and reversible upon discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Chest pain, chest tightness, flushing, hypertension, palpitations, septic shock syncope, tachycardia, vasodepressor syncope</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Anxiety, chills, choking sensation, disturbed sleep, dizziness, drowsiness, dystonia, headache, increased body temperature (may be drug-induced or due to postabortion endometritis), lethargy, nervousness, paresthesia, shivering, vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Diaphoresis, skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hot flash, increased thirst, thyroid storm</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea (approximately 67%), vomiting (approximately 67%), nausea (approximately 33%), dysgeusia, epigastric pain, gag reflex, hematemesis, hiccups, retching, xerostomia</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Breast tenderness, cervical perforation (posterior), endometritis (from intrauterine device [IUD]), gynecological pain (dysmenorrhea-like pain), retained placenta (fragment), urinary tract infection, uterine perforation, uterine rupture, sacculation of uterus, uterine hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Pain at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Back pain, leg cramps, myalgia, torticollis, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blepharospasm, blurred vision, eye pain</p>
<p style="text-indent:-2em;margin-left:2em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Asthma, bronchospasm, cough, dry throat, dyspnea, epistaxis, hyperventilation, pulmonary edema, respiratory distress, throat irritation (fullness of throat), upper respiratory tract infection, wheezing</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Hypersensitivity reaction (includes anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema)</p></div>
<div class="block coi drugH1Div" id="F146270"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to carboprost tromethamine or any component of the formulation; acute pelvic inflammatory disease; active cardiac, pulmonary, renal, or hepatic disease.</p></div>
<div class="block war drugH1Div" id="F146257"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fever: Transient fever may be observed with treatment and is believed to be due to carboprost’s effect on hypothalamic thermoregulation; use caution to distinguish between fever induced by the drug and fever associated with postabortion endometritis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: Pretreatment or concomitant use of antiemetic and antidiarrheal agents is recommended to decrease the incidence of gastrointestinal effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Increased blood pressure may be observed with treatment; degree of hypertension observed is generally moderate and does not require treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: Use with caution in patients with anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use with caution in patients with a history of asthma; therapy may cause transient bronchoconstriction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease, including hypotension or hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Compromised uteri: Use oxytocic agents with caution in patients with compromised (scarred) uterus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic disease, including jaundice.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Potent oxytocic agent: <b>[US Boxed Warning] Potent oxytocic agent; use only with strict adherence to recommended dosing. Carboprost should be used only by medically-trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities. </b></p></div>
<div class="block foc drugH1Div" id="F146266"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemabate: 250 mcg/mL (1 mL) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mcg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mcg/mL (1 mL)</p></div>
<div class="block geq drugH1Div" id="F146253"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323042"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Carboprost Tromethamine Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg/mL (per mL): $158.40 - $382.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hemabate Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg/mL (per mL): $168.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Carboprost Tromethamine Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg/mL (per mL): $150.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866203"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemabate: 250 mcg/mL (1 mL) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mcg/mL (1 mL)</p></div>
<div class="block adm drugH1Div" id="F146268"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IM: Administer deep IM (use a tuberculin syringe for termination of pregnancy); rotate site if repeat injections are required. Do not inject IV</p></div>
<div class="block hazard drugH1Div" id="F51112429"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Carboprost may cause reproductive toxicity and has a structural/toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. Double gloving and a protective gown are recommended for IM administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F146267"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Termination of pregnancy:</b> For aborting pregnancy between week 13 and 20 of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: Failure of expulsion of the fetus during the course of treatment by another method; premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Refractory postpartum uterine hemorrhage:</b> Treatment of postpartum hemorrhage due to uterine atony that has not responded to conventional methods of management. Prior treatment should include the use of intravenously (IV) administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations.</p></div>
<div class="block cyt drugH1Div" id="F13298974"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F146261"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Oxytocic Agents: Carboprost Tromethamine may enhance the adverse/toxic effect of Oxytocic Agents. Specifically, oxytocic effects may be enhanced. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F3198105"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">When used for termination of pregnancy, carboprost is not considered feticidal, but is used to terminate pregnancy due to its ability to stimulate uterine contractions; use is not indicated if the fetus has reached a stage of viability in utero. Complete termination of pregnancy may not be induced in ~20% of cases and should therefore be completed in another way.</p></div>
<div class="block brc drugH1Div" id="F16117666"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if carboprost is excreted in breast milk.</p></div>
<div class="block mop drugH1Div" id="F16117992"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Termination of pregnancy: Confirmation of fetal death; cervical exam after termination of pregnancy</p></div>
<div class="block pha drugH1Div" id="F146256"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Carboprost is an analog of naturally occurring prostaglandin F<sub>2</sub> alpha (dinoprost); carboprost stimulates uterine contractility which usually results in expulsion of the products of conception and is used to induce abortion between 13-20 weeks of pregnancy. When used postpartum, hemostasis at the placentation site is achieved through the myometrial contractions produced by carboprost.</p></div>
<div class="block phk drugH1Div" id="F2929990"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Time to peak, serum: IM: 30 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F146271"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Hemabate</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An lie ke | Hemabate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Prostin 15m</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Hemabate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Hemabate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Caboprost | Deviprost | Evacarb | Femiprost</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Endoprost</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Hemabate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Prostin 15m</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Prostin 15m</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Prostin 15M orifarm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Prostin 15m</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Endoprost | Evacarb | Evaprost | Prostodin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Prostinfenem</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Carboprost tromethamine | Hemabate</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Hemabate</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Hemabate</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Karboprost | Questran</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Hemabate</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Hemabate</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Endoprost</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USPNF.1">
<a name="USPNF.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboprost-tromethamine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboprost-tromethamine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hemabate.1">
<a name="Hemabate.1"></a>Hemabate (carboprost tromethamine injection) [prescribing information]. New York, NY: Pfizer; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboprost-tromethamine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7502421">
<a name="7502421"></a>Ippoliti C, Przepiorka D, Mehra R, et al, “Intravesicular Carboprost for the Treatment of Hemorrhagic Cystitis After Marrow Transplantation,” <i>Urology</i>, 1995, 46(6):811-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboprost-tromethamine-drug-information/abstract-text/7502421/pubmed" id="7502421" target="_blank">7502421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8455230">
<a name="8455230"></a>Levine LA, Jarrard DF. Treatment of cyclophosphamide-induced hemorrhagic cystitis with intravesical carboprost tromethamine. <i>J Urol</i>. 1993;149(4):719-723. doi:10.1016/s0022-5347(17)36192-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboprost-tromethamine-drug-information/abstract-text/8455230/pubmed" id="8455230" target="_blank">8455230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.2016">
<a name="NIOSH.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed February 9, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9250547">
<a name="9250547"></a>West NJ, “Prevention and Treatment of Hemorrhagic Cystitis,” <i>Pharmacotherapy</i>, 1997, 17(4):696-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboprost-tromethamine-drug-information/abstract-text/9250547/pubmed" id="9250547" target="_blank">9250547</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9203 Version 249.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
